摘要
目的:明确孤儿核受体-雌激素受体相关受体(Estrogen receptor-related receptors,ERRs)α-1亚型在卵巢癌组织中的表达情况及其临床意义。方法:采用实时荧光定量RT-PCR和免疫组化方法检测人ERRα-1在45例卵巢癌组织标本和15例正常卵巢组织中的mRNA和蛋白表达情况;采用ELISA方法分析各样本的血清CA125水平;随访指标为整体生存时间和无瘤生存时间。结果:免疫组化分析表明ERRα-1在卵巢癌组织中的表达率显著高于正常组织(P<0·05)。定量PCR分析表明卵巢癌组织中ERRα-1的mRNA平均表达丰度显著高于正常卵巢组织(P<0·05)。卵巢癌患者血清CA125水平分析显示ERRα-1阳性组CA125明显升高(P<0·05)。随访结果显示ERRα-1阳性的卵巢癌患者的整体生存时间比ERRα-1阴性患者明显减少(P<0·05),但两组无瘤生存时间并无差异(P>0·05)。结论:ERRα-1可能在卵巢癌的发生发展中起重要作用,ERRα-1表达增加与卵巢癌的预后不良有关。
Objective： To determine human estrogen receptor - related receptor - α - 1 （ ERRα）, a member of orphan receptors in the tumorogenesis of ovarian cancer. Methods： To analyze the expression of ERRα, real - time quantitative RT - PCR and Western - blot were used to detect ERRα mRNA and protein in 45 primary ovarian cancer samples and 15 normal ovarian samples. Serum CA 125 was also assayed by ELISA in these patients. Progression - free survival and overall survival of patients with different expression of ERRα- 1 were analyzed by Kaplan - Meier method. Results： Positive - expression rate of ERRα - 1 in ovarian cancers were significant higher than that in norreal ovarian tissue （P 〈0. 05）. The mean CA125 level in ERRα- 1 positive samples were significant higher than it in ERRor - 1 negative （ P 〈 0. 05） ; Survival analysis showed ERRα- 1 positive group with a poorly overall survival （ P 〈 0. 05）, while the progression - free survival had no significance （P 〈 0. 05） . Conclusion： ERRα - 1 plays important roles in the treatment of ovarian cancer. ERRα - 1 represents a poor prognosis biomarker in ovarian cancer.
出处
《中国妇幼保健》
CAS
北大核心
2008年第17期2423-2425,共3页
Maternal and Child Health Care of China
基金
国家自然科学基金资助项目(资助序列号:30600666)
德国奔驰-戴姆勒科学研究基金资助(17/05-03)
德国卵巢癌数据库(Tumor Bank Ovarian Center
TOC)合作项目
